作者
Kazuma Oyama, Remo HM Furtado, Antonio Fagundes Jr, Thomas A Zelniker, Minao Tang, Julia Kuder, Sabina A Murphy, Andrew Hamer, Huei Wang, Anthony C Keech, Robert P Giugliano, Marc S Sabatine, Brian A Bergmark
发表日期
2021/1/26
期刊
Journal of the American College of Cardiology
卷号
77
期号
3
页码范围
259-267
出版商
American College of Cardiology Foundation
简介
Objectives
This study sought to evaluate the ability of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to reduce the risk of complex coronary atherosclerosis requiring revascularization.
Background
PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization overall.
Methods
FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) was a randomized trial of the PCSK9 inhibitor evolocumab versus placebo in 27,564 patients with stable atherosclerotic cardiovascular disease on statin therapy followed for a median of 2.2 years. Clinical documentation of revascularization events was blindly reviewed to assess coronary anatomy and procedural characteristics. Complex revascularization was the composite of complex percutaneous coronary intervention (PCI) (as per previous analyses, ≥1 of …
学术搜索中的文章
K Oyama, RHM Furtado, A Fagundes Jr, TA Zelniker… - Journal of the American College of Cardiology, 2021